Clinical trial · Interventional
IMRT With Carboplatin Versus IMRT With Carboplatin and Fluorouracil for Eldly Esophageal Cancer Patients
IMRT Combined With Carboplatin Versus IMRT Combined With Carboplatin and Fluorouracil in the Treatment of Locally Advanced Esophageal Cancer in Elderly Patients With High Risk of Chemotherapy: a Randomized Controlled Clinical Study
NCT03910634CI-TRIAL-00038044unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An open, single-center, randomized controlled phase II clinical trial to compare the efficacy and safety of conformal intensity modulated radiation therapy (IMRT) combined with carboplatin and IMRT combined with carboplatin and 5-FU in elderly patients with locally advanced esophageal squamous cell carcinoma at high risk of chemotherapy
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Radiotherapy Side Effect | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin | Drug | Carboplatin | ALIAS |
| Fluorouracil | Drug | Fluorouracil | ALIAS |
| Intensity modulated radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- IMRT combined with carboplatin
- description
- Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
- interventionNames
- Radiation: Intensity modulated radiation therapy
- Drug: carboplatin
- type
- PLACEBO_COMPARATOR
- label
- IMRT combined with carboplatin and fluorouracil
- description
- Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip; Fluorouracil 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
- interventionNames
- Drug: Fluorouracil
- Radiation: Intensity modulated radiation therapy
- Drug: carboplatin
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Age (\> 65 years) * Histologically confirmed esophageal squamous cell carcinoma, the 8th edition of AJCC stage T3-4NxM0 or TxN1-3M0, without surgical indications after consultation by surgeons. * PS score \< 2, Chemotherapy risk score is medium and high risk * No radical thoracic surgery/chemotherapy/radiotherapy/targeted therapy has been performed in the past. * Diseases measurable according to RECIST standards * Hematological examination requires Hb (\>90g/L), ANC (\>2.0 \*109/L) and platelet (\>100 \*109/L). Serum albumin (\>3.0g/dL) * Serum creatinine \< 1.25 times normal upper limit (UNL), or creatinine clearance rate (\>60 ml/min). Total bilirubin \< upper limit of normal value * Total bilirubin \< the upper limit of normal value, AST (SGOT) and ALT (SGPT) \< 2.5 times the upper limit of normal value, ALP \< 2.5 times the upper limit of normal value (ULN) * If exploratory surgery is performed, the patient will recover at least 2 weeks after operation. Exclusion Criteria: * Pregnant or lactating women. * Patients with fertility without adequate contraceptive measures. * Anaphylaxis to 5FU and carboplatin is known. * Anaphylaxis known to exist with any drug in the study * Other malignant tumors have occurred in the past five years, except cervical carcinoma in situ or non-melanoma skin cancer, which has been properly treated. * Discovery of esophageal fistula or risk of esophageal bleeding before treatment * Distant organ metastasis is known * Symptomatic peripheral neuropathy, according to NCIC-CTC criteria (\> grade 2). * Other serious diseases or medical conditions: Myocardial infarction (in the past six months), severe unstable angina pectoris and congestive heart failure have occurred. * Severe complications (including intestinal paralysis, intestinal obstruction, interstitial pneumonia, pulmonary fibrosis, severe respiratory dysfunction of COPD, cardiac dysfunction of pulmonary heart disease, uncontrolled diabetes mellitus, renal insufficiency and cirrhosis of liver, etc.) * Gastrointestinal bleeding requires frequent blood transfusion. * It is known to carry human immunodeficiency virus (HIV) or AIDS. * Suffering from mental illness * The known neuropathy is of grade 2 or higher severity.
References
Publications (0)
Data not yet available
No reference posted for this study.